L’Oréal to Acquire Majority Stake in Medik8

L’Oréal has announced it will acquire a majority stake in British skincare brand Medik8. The brand will become the latest addition to L’Oréal’s expanding portfolio of premium, science-led beauty names, further strengthening the L’Oréal Luxe division.

Founded by scientist Elliot Isaacs, Medik8 has built a loyal following for its results-driven formulas, led by its hero product, Crystal Retinal, and its trademark CSA Philosophy: Vitamin C and Sunscreen application by day, Vitamin A application by night. Known for delivering ‘results without compromise’, the brand has evolved from its professional roots into a successful omnichannel business, with a strong footprint across Europe and growing momentum in the US.

As part of the transaction, private equity firm Inflexion will retain a minority share. Medik8’s founder will remain on the board, and the current management team will stay in place to ensure continuity as the brand enters its next phase.

“We are delighted to welcome Medik8 to the L’Oréal family,” said Cyril Chapuy, President of L’Oréal LUXE. “As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio. We share a strong belief in Medik8’s global potential and are excited to embark on this journey together, to build a powerful and impactful brand presence worldwide.”

“This is an exciting day for Medik8,” added Simon Coble, CEO of Medik8. “I am delighted to be joining forces with a company which shares our vision for the brand’s future growth and whose core values align with our deep commitment to science, innovation and above all, results without compromise. I look forward to the next stage in Medik8’s journey, as we work together to bring our innovative products to a wider audience.”

L’Oréal, which celebrated its 115th anniversary in 2024, generated €43.48 billion in sales that year. The company operates 21 research centres across 13 countries and employs more than 90,000 people worldwide.

The acquisition is expected to close in the coming months, pending regulatory approvals and customary conditions. L’Oréal will begin consolidating Medik8’s sales upon completion and has also secured the rights to fully buy out the remaining minority shareholders in the future.